You have read all your free articles, to continue reading subscribe to read the rest of this content.
BioInvent International receives a milestone payment from Bayer/Hope Medicine following clinical progression of an out-licensed antibody. BioInvent receives EUR 500,000 following the enrollment of the first patient in a Phase 2 trial of HMI-115 for the treatment of endometriosis in pre-menopausalAlready a subscriber Login You have read all your free…
The purpose of the share issue is to fund an enhanced clinical trial program that can shorten the development time and increase the commercial potential of the company's drug candidate TOL2 – one of the company's potentially curative treatments for severe autoimmune diseases. TOL2, is being devAlready a subscriber Login…
Idogen has initiated a collaboration with Richard Williams’ research group at the Kennedy Institute of Rheumatology at the University of Oxford. Using a research model of rheumatoid arthritis, the collaboration will investigate the treatment effect of follow-up molecules to Zebularine, whichAlready a subscriber Login You have read all your free articles, to continue…
IRLAB Therapeutics has announced that its CEO Richard Godfrey is leaving his position and that the Board of directors has appointed Gunnar Olsson as Interim CEO. This news follows the disappointing Phase IIb trial results of mesdopetam in people with Parkinson's disease levodopa-induced dyskinesiAlready a subscriber Login You have read…
